1.. Introduction {#s0001}
================

Hypoxia is one of the most complex conditions that cellular and extracellular matrix confront in order to preserve their homeostasis[@CIT0001]. Bearing the hallmarks of cancer in mind as described by Hanahan and Weinberg, hypoxic metabolic reprogramming elicits complex mechanisms which take place in the microenvironment of many solid tumours[@CIT0002]^,^[@CIT0003]. Two of the key transcription factors that play major roles in this metabolic reprogramming are the hypoxia inducible factors (HIFs), namely HIF-1α and HIF-2α[@CIT0004]. Carbonic anhydrase IX (CAIX) is a HIF-1α-dependent protein that regulates cellular and extracellular pH homeostasis under hypoxia, playing a pivotal role in carcinogenesis and in the malignant transition of premalignant disorders[@CIT0005]. Several studies have evaluated the prognostic value of CAIX in different types of cancer, including oral squamous cell carcinoma (OSCC)[@CIT0008]^,^[@CIT0009].

OSCC accounts for 95% of all oral malignant neoplasms and its global five-year survival rate ranges between 50 and 60%[@CIT0010]. The TNM cancer staging system is still considered to be of great prognostic value for this solid tumour[@CIT0011]. Nonetheless, this system cannot be used to accurately predict the biologic properties of OSSC, nor can it be used to provide guidance for treatment strategies from a molecular biology perspective. Analysing molecular alterations in order to detect specific abnormalities at a transcriptional, translational, and post-translational level has proven to be of particular interest[@CIT0012]^,^[@CIT0013]. In this line, immunohistochemistry (IHC) -- the use of mono and polyclonal antibodies to determine the tissue distribution of an antigen -- has an outstanding oncological impact[@CIT0014]. Nonetheless, the clinical translation of these IHC-based approaches in terms of decision-making, remains suboptimal for many solid tumours[@CIT0014]^,^[@CIT0015].

There is growing evidence which confirms the key role of CAIX in oral oncogenesis. Numerous publications have explored a possible relationship between CAIX expression and OSCC prognosis, as well as the rate of progression from oral potentially malignant disorders to OSCC[@CIT0016].

The only meta-analysis carried out on this issue so far did not assess the prognostic value in subgroups[@CIT0019]. It is known that the prognosis of head and neck cancers is different through tumour locations. It is then of paramount importance to carry out subgroup analyses[@CIT0020].

We, therefore, decided to perform a systematic review and meta-analysis on the influence of CAIX expression on the long-term outcomes of patients suffering from OSCC.

2.. Material and methods {#s0002}
========================

2.1.. Protocol and eligibility criteria {#s0003}
---------------------------------------

A systematic literature review was conducted in November 2019 and the protocol used adhered to the PRISMA guidelines[@CIT0021]. The search question was formulated according to the PECO framework, and it read as follows: What is the prognostic value of tumoural CAIX immunohistochemical expression in patients with OSCC?

2.2.. Sources {#s0004}
-------------

Electronic searches were carried out in MEDLINE *via* PubMed, EMBASE *via* OVID, Web of Science, Scopus, the WHO five regional bibliographic databases (AIM, LILACS, IMEMR, IMSEAR, and WPRIM), and the Conference Proceedings Citation Index databases. For Medline, the following algorithm was used both in the Medical Subject Heading and in the free text words: ("CAIX") OR ("ca9") OR ("carbonic anhydrase IX") OR ("carbonic anhydrase 9") OR ("carbonic anhydrase-IX") OR ("carbonic anhydrase-9") OR ("CA-IX") OR ("ca-9") OR ("G250") AND ("carcinoma, squamous cell" OR "carcinoma" AND "squamous" AND ("cell") OR "squamous cell carcinoma") OR ("mouth neoplasm"). The aforementioned syntax was conveniently adapted for each database. All of the databases were searched from inception to August 2019. This process was complemented by a manual search in a series of peer-reviewed journals with related content. Potentially relevant articles that any of the authors were familiar with, as well as reference lists from the retrieved articles, were also comprehensively checked. In these searches, no language restrictions were applied.

2.3.. Study selection and data extraction process {#s0005}
-------------------------------------------------

The study eligibility criteria were applied independently by two trained reviewers (A.I.L.P. and M.P.S.). Any discrepancies were resolved by consensus of all participating authors.

Criteria for eligibility for retrieved studies in the qualitative/quantitative analysis were as follows: i) original research articles published in any language; ii) assessing CAIX expression in biopsies from patients with OSCC using IHC methods; iii) analysing the association between CAIX overexpression with any of the following long-term outcomes: overall survival (OS), disease-free survival (DFS), locoregional control (LC), and disease-specific Survival (DSS). The exclusion criteria were as follows: i) case reports, editorials, or letters; *in vitro* or animal-based studies; ii) insufficient statistical data to estimate predefined outcomes; iii) studies evaluating CAIX protein-related genes or miRNAs; iv) studies with duplicated cohorts.

In the first round, the title and abstract of the retrieved articles and studies which met the inclusion criteria were read and any texts which presented insufficient data in order for a clear decision to be made were assessed following a full-text protocol. Subsequently all of the studies which were considered eligible were fully examined in a second round and the final decision as to whether or not they were to be included was made. This form included the following items: first author, year of publication, country and continent where the study was conducted, sample size, recruitment period, tumour subsite, treatment modality, follow-up period, cut-off value for CAIX IHC positivity, immunostaining pattern (nuclear/cytoplasmic), hazard ratios (HRs) for long-term outcomes, and adjustment variables.

2.4.. Quality assessment, data synthesis, and analysis {#s0006}
------------------------------------------------------

Quality was independently assessed by two authors (O.A.C. and C.M.C.P.) by means of a variation of the criteria formulated in the Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) guidelines for prognostic studies and the Standards for Reporting of Diagnostic Accuracy (STARD) developed by Troiano et al[@CIT0022]. This variation included six dimensions which evaluated:Samples: i) Cohort (retrospective or prospective) study with a well-defined study population; ii) Medical treatment applied to the patients was explained. Authors have explained if all patients have received the same treatment or not.Clinical data of the cohort: The basic clinical data such as age, gender, clinical stage, and histopathological grade was provided.IHC: Well-described staining protocol or referred to original paper.Prognosis: The analysed survival endpoints were well defined (e.g. OS and DFS).Statistics: i) Cut-off point, which is used to divide the cases into risk groups was well described; ii) Estimated effect describing the relationship between the evaluated biomarker and the outcome was provided; (iii) Adequate statistical analysis (e.g. Cox regression modelling) was performed to adjust the estimation of the effect of the biomarker for known prognostic factors.Classical prognostic factor: The prognostic value of other classical prognostic factors and its relationship with the studied factor was reported.

Each parameter could be identified by one of three attributes (i.e. adequate \[A\], inadequate \[I\], or non-evaluable \[N/A\]. Each item scored as adequate adds one point to overall quality assessment for each study. A score sheet was prepared for each included study and quality scoring was independently undertaken by aforementioned author. In the event of disagreement, the scores were discussed until a consensus was reached. Studies were categorised as high quality when the overall score was \>4.

The differences in the levels of CAIX staining were categorised as high and low, according to the cut-off value which was chosen by the authors of the studies. HRs and 95% confidence intervals (CIs) were used as the measure of association in order to estimate the impact of CAIX expression on the aforementioned long-term outcomes (OS, DFS, LC, and DSS). Multivariate or univariate HRs values were used but, when available, the formers were chosen. When data on the HRs could not be directly traced, these were calculated using the approximation methods described by Parmar et al.[@CIT0023] and Tierney et al.[@CIT0024]. Lastly, when access was provided to full databases, the HRs were directly extracted.

Pooled analyses were obtained using both fixed-effect models (i.e. Mantel--Haenszel method) and random-effect models (i.e. DerSimonian and Laird method), but when substantial heterogeneity was detected, we based our assessment only on random-effects models. A subgroup analysis on the basis of several variables was planned (i.e. quality score, ethnic variations, tumour subsite, CAIX antibody, cut-off point, and type of covariate adjustment). The heterogeneity was assessed using the proportion of the total variance due to the variance between studies (R~i~)[@CIT0025]. Large values (\>0.75) indicate a large amount of heterogeneity, values between 0.4 and 0.75 suggest a moderate amount, whereas small values (\<0.4) indicate a low amount of heterogeneity. Funnel plots were used to visually assess publication bias and the Egger's test was used in order to conduct a more formal analysis. Stata version 14.1 (Stata Corp, College Station, TX, US) and HEpiMA version 2.1.3 (Corunna, Galicia, Spain) were employed[@CIT0026].

3.. Results {#s0007}
===========

3.1.. Characteristics of the included studies {#s0008}
---------------------------------------------

Out of the 1741 publications which were initially retrieved, 18 studies met our inclusion criteria and were included in the meta-analysis, as depicted in [Figure 1](#F0001){ref-type="fig"}. The studies reported on a total of 1616 OSCC-affected patients[@CIT0027].

![Flowchart for inclusion of the studies according to the PRISMA guidelines.](IENZ_A_1772250_F0001_C){#F0001}

![Forest plot for the association of higher CAIX expression with overall survival (A), disease‐free survival (B).](IENZ_A_1772250_F0002_B){#F0002}

The data was collected in a period spanning from 1987 to 2015[@CIT0027] while the year of publication ranged from 2008 to 2019. The anatomic location of the tumours was mainly divided into exclusively tongue[@CIT0027]^,^[@CIT0028]^,^[@CIT0030]^,^[@CIT0031]^,^[@CIT0037]^,^[@CIT0039]^,^[@CIT0042], or mixed subsite tumours [@CIT0029]^,^[@CIT0032]^,^[@CIT0038]^,^[@CIT0040]^,^[@CIT0041]. The population sample ranged from 21 in Roh et al. study[@CIT0030] to 271 in Yang et al. study[@CIT0038]. The studies were carried out in Asia, Europe, and America. Half of the studies were carried out in Asia (specifically in China[@CIT0038], Japan[@CIT0027]^,^[@CIT0033], and South Korea[@CIT0028]^,^[@CIT0032]^,^[@CIT0035]^,^[@CIT0037]) and the other half in Brazil[@CIT0039]^,^[@CIT0043], Canada[@CIT0034], Germany[@CIT0031]^,^[@CIT0044], Portugal[@CIT0040], Spain[@CIT0036]^,^[@CIT0040]^,^[@CIT0042], and the US[@CIT0041]. The retrieved data are summarised in [Table 1](#t0001){ref-type="table"}. The individual HRs for each selected long-term outcome with its respective adjustment is reflected in [Table 2](#t0002){ref-type="table"}. The authors had full access to three full databases[@CIT0036]^,^[@CIT0040]^,^[@CIT0042]. An article-based doctoral dissertation retrieved *via* LILACS needed to be fully assessed for its HR estimation[@CIT0039].

###### 

Characteristics of the included studies.

  Study                                          Year   Country            Sample size   Tumour subsite                                                                                                 Recruitment period   Treatment        Follow-up (months)         CAIX antibody                                            IHC pattern            Cut-off point (%)                 CAIX (+)
  ---------------------------------------------- ------ ------------------ ------------- -------------------------------------------------------------------------------------------------------------- -------------------- ---------------- -------------------------- -------------------------------------------------------- ---------------------- --------------------------------- --------------------
  Sakata K et al. \[[@CIT0027]\]                 2008   Japan              68            Tongue                                                                                                         1987--2004           Rx               11--146 (mean 56)          Rabbit polyclonal antibody to CAIX (Novus Biologicals)   Membrane               10                                32.35% (*n* = 22)
  Kim SJ et al. \[[@CIT0028]\]                   2007   South Korea        60            Tongue                                                                                                         1997--2004           Sx, and Rx       4.1--117.13 (mean 29.51)   Anti-CAIX mouse monoclonal antibody clone M75            Cytoplasmic membrane   10                                63.33% (*n* = 38)
  Choi SW et al. \[[@CIT0029]\]                  2008   South Korea        117           Buccal mucosa, gingiva, tongue, retromolar trigone, palate, and lip.                                           1996--2000           Sx, and Rx       2--120 (mean 39.5)         Anti-CAIX mouse monoclonal antibody clone M75            Cytoplasmic membrane   5                                 58.12% (*n* = 68)
  Roh JL et al. \[[@CIT0030]\]                   2009   South Korea        21            Tongue                                                                                                         1997--2005           Sx, and Rx       37--123 (mean 60)          Monoclonal antibody CAIX (AF 2188)                       Cytoplasmic membrane   10                                60.47% (*n* = 26)
  Eckert AW et al. \[[@CIT0031]\]                2010   Germany            80            Hard and soft palate, buccal mucosa, tongue, floor of the mouth, mandibular angle, and lower alveolar mucosa   1994--1999           Sx               60                         Monoclonal antibody CAIX (HI-20, SC25599)                Cytoplasmic membrane   10                                42.5% (*n* = 34)
  Han MW et al. \[[@CIT0032]\]                   2011   South Korea        33            Tongue                                                                                                         2001--2006           Sx, and Rx       40 (range 9--113)          Monoclonal antibody CAIX (AF 2188)                       Cytoplasmic membrane   10                                63.6% (*n* = 21)
  Kondo Y et al. \[[@CIT0033]\]                  2011   Japan              107           Tongue, gingiva, floor of mouth, lips, and buccal mucosa                                                       1992--2009           Sx               60                         Rabbit polyclonal to CAIX (Abcam 15086)                  Membrane               10                                91.58% (*n* = 98)
  Brockton NT et al. \[[@CIT0034]\]              2012   Canada             61            Unspecified oral cancer                                                                                        1998--2005           Sx and Rx        60                         Rabbit polyclonal to CAIX (Abcam 15086)                  N/A                    [\*](#TF2){ref-type="table-fn"}   26.23% (*n* = 16)
  Heo K. \[[@CIT0035]\]                          2012   South Korea        62            Tongue and others                                                                                              2003--2006           N/A              52.2 (range 5.75--86.9)    Anti-CAIX mouse monoclonal antibody clone M75            Cytoplasmic membrane   10                                69.35% (*n* = 41)
  Pérez-Sayáns M et al. \[[@CIT0036]\]           2012   Spain              50            Buccal mucosa, soft palate, gums, retromolar trigone, tongue, and floor of the mouth                           2006--2010           Rx, Qx, and Sx   28.7--37.9                 Anti-CAIX mouse monoclonal antibody clone M75            Cytoplasmic membrane   10                                82.00% (*n* = 41)
  Hwa JS et al. \[[@CIT0037]\]                   2015   South Korea        24            Tongue                                                                                                         1998--2009           Rx, Qx, and Sx   11--116 (mean 56)          Rabbit polyclonal antibody to CAIX (Novus Biologicals)   Membrane               10                                20.83% (*n* = 5)
  Yang JS et al. \[[@CIT0038]\]                  2015   Taiwan             271           Unspecified oral cancer                                                                                        2000--2006           N/A              150 months                 Anti-CAIX antibody (Santa Cruz Biotechnology)            N/A                    N/A                               41.69% (*n* = 113)
  Vasconcelos MG et al. \[[@CIT0039]\]           2015   Brazil             57            Tongue                                                                                                         1995--2007           N/A              N/A                        Anti-CAIX antibody (Santa Cruz Biotechnology)            Cytoplasmic membrane   10                                66.7% (*n* = 38)
  Simoes-Sousa S et al. \[[@CIT0040]\]           2016   Brazil and Spain   135           Tongue, floor of mouth, buccal mucosa, gingiva, and retromolar trigone                                         NA                   Rx, Qx, and Sx   105 months                 Antibody CAIX (Abcam 15086)                              Cytoplasmic membrane   5                                 57.78% (*n* = 78)
  Brockton NT et al. \[[@CIT0041]\]              2017   USA                168           Tongue, floor of mouth, buccal mucosa, and gingiva                                                             2003--2012           Rx, Qx, and Sx   33 (range 0.2--111.0)      Rabbit polyclonal CAIX (Abcam 15086)                     N/A                    [\*](#TF2){ref-type="table-fn"}   25.00% (*n* = 42)
  Sáenz-de-Santa-María I et al. \[[@CIT0042]\]   2017   Spain              108           Tongue                                                                                                         N/A                  N/A              N/A                        Antibody Carbonic CAIX (Abcam 15086)                     Cytoplasmic membrane   23                                48.15% (*n* = 52)
  Peterle GT et al. \[[@CIT0043]\]               2018   Brazil             52            Unspecified oral cancer                                                                                        2002--2008           Sx and Rx        24--60 months              Antibody CAIX (Abcam 108351)                             Cytoplasmic membrane   25                                50.00% (*n* = 26)
  Eckert AW et al. \[[@CIT0044]\]                2019   Germany            158           Unspecified oral cancer                                                                                        1997--2015           Sx               105 months                 Anti-CAIX mouse monoclonal antibody clone M75            N/A                    51                                15.19% (*n* = 24)

N/A: not available; Qx: chemotherapy; Rx: radiotherapy; Sx: surgery

\*Raw AQUA score distributions for CAIX were evaluated: high CAIX expression was defined as an AQUA score within the upper quartile. Low CAIX expression was defined as an AQUA score within the lower three quartiles.

###### 

Synthesis of data extracted from the included studies related to outcomes pooled in the meta‐analysis.

  Study                                          OS (HR 95% CI)       DFS (HR 95% CI)      LC (HR 95% CI)      DSS (HR 95% CI)     Adjustment
  ---------------------------------------------- -------------------- -------------------- ------------------- ------------------- ------------------------------------------------------------------------------
  Sakata K et al. \[[@CIT0027]\]                 NR                   NR                   0.91 (0.32--2.61)   NR                  Multivariate adjusted for T stage and microvessel density.
  Kim SJ et al. \[[@CIT0028]\]                   2.99 (1.39--6.45)    1.76 (0.89--3.51)    NR                  NR                  None
  Choi SW et al. \[[@CIT0029]\]                  1.91 (0.77--4.71)    1.77 (0.56--5.56)    NR                  NR                  None
  Roh JL et al. \[[@CIT0030]\]                   NR                   NR                   1.09 (0.43--2.76)   0.71 (0.23--2.22)   None
  Eckert et al. \[[@CIT0031]\]                   1.34 (0.65--2.76)    NR                   NR                  NR                  Multivariate adjusted for tumour size and tumour grade.
  Han MW et al. \[[@CIT0032]\]                   0.65 (0.12--3.67)    0.80 (0.50--3.15)    NR                  NR                  Multivariate adjusted for tumour size and tumour grade.
  Kondo Y et al. \[[@CIT0033]\]                  3.36 (0.97--11.70)   NR                   NR                  NR                  None
  Brockton NT et al. \[[@CIT0034]\]              NR                   NR                   NR                  2.96 (1.01--8.66)   Multivariate adjusted for tumour stage and nodal involvement.
  Heo K et al. \[[@CIT0035]\]                    NR                   6.82 (1.22--37.94)   NR                  NR                  None
  Pérez-Sayáns M et al. \[[@CIT0036]\]           1.36 (0.43--4.26)    NR                   NR                  2.04 (0.76--5.49)   None
  Hwa JS et al. \[[@CIT0037]\]                   NR                   NR                   NR                  0.29 (0.05--1.77)   None
  Yang JS et al. \[[@CIT0038]\]                  1.76 (1.07--2.87)    NR                   NR                  NR                  None
  Vasconcelos MG et al. \[[@CIT0039]\]           0.86 (0.23--3.26)    NR                   NR                  NR                  None
  Simoes-Sousa S et al. \[[@CIT0040]\]           0.76 (0.44--1.38)    NR                   NR                  NR                  None
  Brockton NT et al. \[[@CIT0041]\]              NR                   NR                   NR                  1.0 (1.00--1.01)    Multivariate adjusted for tumour stage and nodal involvement.
  Sáenz-de-Santa-María I et al. \[[@CIT0042]\]   1.14 (0.69--1.89)    NR                   NR                  NR                  Multivariate adjusted for tumour stage and nodal involvement.
  Peterle GT et al. \[[@CIT0043]\]               NR                   8.75 (0.99--77.19)   NR                  2.84 (1.02--7.87)   Multivariate adjusted for tumour size and the use of Rx.
  Eckert AW et al. \[[@CIT0044]\]                1.70 (0.97--2.85)    NR                   NR                  NR                  Multivariate adjusted for tumour stage, lymph node status, and tumour grade.

NR: no report.

3.2.. Quality assessment and pooled analysis of the included studies {#s0009}
--------------------------------------------------------------------

The quality assessment which was performed in accordance with the REMARK guidelines is summarised in [Table 3](#t0003){ref-type="table"}. According to these criteria ten studies showed a good quality, although eight were considered at high risk of bias. [Table 4](#t0004){ref-type="table"} lists the pooled effect estimates for all 18 studies, for each of the selected long-term outcomes, as well as the analysis of its subgroups. A fixed-effects model was used to evaluate the pooled HR with 95% CI for the outcomes of OS, DFS, and LC, given that they displayed low heterogeneity. A random-effects model was used for DSS due to its high heterogeneity. A higher CAIX expression is associated with a statistically significant worse OS (HR = 1.45, 95% CI 1.17--1.80), and in the case of DFS, the pooled analysis reflected almost a two-fold increase in the hazard for this outcome (HR = 1.98, 95% CI 1.18--3.32). However, higher CAIX expression is apparently not related to LC (HR = 1.01, 95% CI 0.50--2.02), nor to DSS (HR = 1.35, 95% CI 0.78--2.33).

###### 

Quality score according to the REMARK guidelines.

  Study                                          Year   Samples   Clinical data of the cohort   Immunohisto chemistry   Prognosis   Statistics   Classical prognostic factors   Overall risk of bias
  ---------------------------------------------- ------ --------- ----------------------------- ----------------------- ----------- ------------ ------------------------------ ----------------------
  Sakata K et al. \[[@CIT0027]\]                 2008   A         I                             A                       I           I            I                              2
  Kim SJ et al. \[[@CIT0028]\]                   2007   A         A                             A                       A           A            A                              6
  Choi SW et al. \[[@CIT0029]\]                  2008   A         A                             A                       I           A            A                              5
  Roh JL et al. \[[@CIT0030]\]                   2009   A         A                             A                       A           A            A                              6
  Eckert AW et al. \[[@CIT0031]\]                2010   A         A                             A                       N/A         I            I                              3
  Han MW et al. \[[@CIT0032]\]                   2011   A         I                             A                       I           A            A                              4
  Kondo Y et al. \[[@CIT0033]\]                  2011   A         A                             A                       A           A            A                              6
  Brockton NT et al. \[[@CIT0034]\]              2012   A         I                             A                       A           A            A                              5
  Heo K et al. \[[@CIT0035]\]                    2012   I         A                             A                       I           A            A                              4
  Pérez-Sayáns M et al. \[[@CIT0036]\]           2012   A         A                             A                       I           A            A                              5
  Hwa JS et al. \[[@CIT0037]\]                   2015   I         A                             A                       I           I            I                              2
  Yang JS et al. \[[@CIT0038]\]                  2015   I         A                             A                       I           A            A                              4
  Vasconcelos MG et al. \[[@CIT0039]\]           2015   A         I                             A                       I           I            A                              3
  Simoes-Sousa S et al. \[[@CIT0040]\]           2016   I         A                             A                       A           A            A                              5
  Brockton NT et al. \[[@CIT0041]\]              2017   A         A                             A                       A           A            A                              6
  Sáenz-de-Santa-María I et al. \[[@CIT0042]\]   2017   A         I                             A                       A           A            I                              4
  Peterle GT et al. \[[@CIT0043]\]               2018   A         A                             A                       I           A            A                              5
  Eckert AW et al. \[[@CIT0044]\]                2019   A         A                             A                       A           A            A                              6

Items were assessed as A: Adequate; I: Inadequate; N/A: no description.

###### 

Pooled hazard ratios and 95% confidence intervals.

                                 Number of studies   Pooled HR (95% CI), fixed effects   Pooled HR (95% CI), random effects   R~i~^\*^   Q test *p* Value
  ------------------------------ ------------------- ----------------------------------- ------------------------------------ ---------- ------------------
  Overall survival                                                                                                                       
   Overall                       11                  1.45 (1.17--1.80)                   1.46 (1.12--1.89)                    0.26       .21
   High quality                  6                   1.48 (1.18--1.86)                   1.51 (1.11--2.06)                    0.38       .13
   Low quality                   5                   1.21 (0.64--2.29)                   1.21 (0.64--2.29)                    0.00       .57
   Full adjustment               4                   1.48 (1.18--1.86)                   1.51 (1.11--2.06)                    0.38       .13
   Asian                         5                   2.01 (1.42--2.86)                   2.01 ( 1.42--2.86)                   0.00       .45
   Non-Asian                     6                   1.19 (0.91--1.57)                   1.19 (0.91--1.57)                    0.00       .45
   Tongue                        4                   1.18 (0.84--1.66)                   1.22 (0.66--2.27)                    0.66       .04
   Mixed subsites                7                   1.48 (1.14--1.91)                   1.48 (1.10--2.00)                    0.22       .29
   Use of M75 antibody           3                   1.93 (1.29--2.88)                   1.93 (1.29--2.88)                    0.00       .39
   Use of other antibodies       8                   1.29 (1.00--1.67)                   1.29 (0.96--1.75)                    0.21       .27
   Use of 10% cut-off point      6                   1.72 (1.14--2.59)                   1.69 (1.06--2.69)                    0.17       .31
   Use of other cut-off points   5                   1.36 (1.06--1.75)                   1.36 (0.98--1.88)                    0.39       .17
  Disease-free survival                                                                                                                  
   Overall                       5                   1.98 (1.18--3.32)                   2.12 (1.02--4.43)                    0.40       .19
   Asian                         4                   1.81 (1.06--3.09)                   1.82 (0.90--3.69)                    0.34       .25
   Tongue                        2                   1.51 (0.79--2.88)                   1.27 (0.43--3.74)                    0.57       .21
   Mixed subsites                3                   3.24 (1.35--7.76)                   3.58 (1.26--10.12)                   0.26       .39
   Use of 10% cut-off point      3                   1.82 (0.99--3.33)                   1.85 (0.59--5.77)                    0.65       .12
   Use of other cut-off points   2                   2.50 (0.91--6.89)                   2.98 (0.69--12.91)                   0.48       .20
  Locoregional control                                                                                                                   
   Overall                       2                   1.01 (0.50--2.02)                   1.01 (0.50--2.02)                    0.00       .80
  Disease specific survival                                                                                                              
   Overall                       6                   1.00 (0.99--1.01)                   1.35 (0.78--2.33)                    1.00       .03
   Asian                         2                   0.55 (0.21--1.44)                   0.55 (0.21--1.44)                    0.00       .41
   Non-Asian                     4                   1.00 (0.99--1.01)                   1.79 ( 0.90--3.54)                   1.00       .01
   Tongue                        2                   0.55 (0.21--1.44)                   0.55 (0.21--1.44)                    0.00       .41
   Mixed subsites                4                   1.00 (0.99--1.01)                   1.79 (0.90--3.54)                    1.00       .02

\*R~i~ stands for the proportion of the total variance due to between studies variance.

The funnel plot for OS ([Figure 3](#F0003){ref-type="fig"}) indicates a minimal skewness to the right that was not confirmed by the Egger's test (P~Egger~ = 0.59). In the case of DFS, this statistical test also indicates the absence of publication bias (P~Egger~ = 0.29).

![Funnel plot of publication bias for higher CAIX expression and overall survival.](IENZ_A_1772250_F0003_B){#F0003}

In the OS subgroup analysis, the statistically significant association was not preserved in the non-Asian (HR = 1.19, 95% CI 0.91--1.57), low quality (HR = 1.21, 95% CI 0.64--2.29), and tongue carcinoma subgroups (HR = 1.18, 95% CI 0.84--1.66). The analysis showed that the pooled HR was twice higher for the Asian group (HR = 2.01, 95% CI 1.42--2.86) when compared to the Non-Asian group. Furthermore, the use of M75 antibody and the choice of a 10% cut-off point were related with increased HR, \[HR = 1.93, 95% CI 1.29--2.88\], and HR =1.72, 95% CI 1.14--2.59), respectively. In the case of DFS, its statistical significance was preserved in the Asian group (HR = 1.81, 95% CI 1.06--3.09), mixed subsites (HR = 3.24, 95% CI 1.35--7.76), and use of other cut-off points than 10% for IHC subgroups (HR = 2.50 95% CI 0.91--6.89) ([Figure 2](#F0002){ref-type="fig"}).

4.. Discussion {#s0010}
==============

Globally, this systematic review and meta-analysis show that CAIX overexpression is correlated with worse OS and DFS in OSCC patients, indicating that positivity for this test implies that the overall risk of dying increases by about 50%. The relation between CAIX expression and OS and DFS appears to confirm the prognostic value that is attributed to this marker on the basis of its relation with the HIF pathway[@CIT0009]^,^[@CIT0045]. CAIX contributes to the tumour microenvironment by maintaining extracellular acidic pH and helping cancer cells grow and metastasise in several other solid tumours[@CIT0005]^,^[@CIT0006].

Our study showed a lower prognostic value for OS and DFS than that shown in Peridis et al.'s study[@CIT0019]. Our study may be more reliable due to the accumulation of studies with high-quality scores and lower heterogeneity across studies. In addition, to our knowledge, our study is the first meta-analysis to measure this prognostic value exclusively in OSCC.

The relative consistency of the results across subgroups reinforces the plausibility of the findings. First, publication bias is a highly unlikely explanation for the present results given the findings of the asymmetry tests of the funnel plot for both OS and DFS ([Figure 3](#F0003){ref-type="fig"}). It is worth mentioning that we observed that a relevant part of the studies included in our meta-analysis did not provide HRs estimates adjusted for relevant cofounders, although subgroup analysis demonstrated that even after the use of fully adjusted models for multiple established OSCC risk factors the OS remained with the same magnitude. Also, the hypoxic nature of these tumours is highly influenced by the crosstalk with other molecular pathways such cell cycle or angiogenesis, and in our review several reports took these factors into account[@CIT0009].

Second, the heterogeneity of the studies included in the present meta-analysis was generally small especially in relation to LC, DFS, and OS ([Table 4](#t0004){ref-type="table"}). On the contrary, there was high heterogeneity in DSS. We relate this finding to the fact that survival parameters were undefined in some studies, largely due to the lack of international consensus on the definitions of long-term outcomes. In the OS subgroup analysis, CAIX overexpression also had a particularly negative impact on the OS of Asian patients. These differences could be linked to genetic and lifestyle variabilities[@CIT0010]. This study also identified that variations at the level of staining protocol also resulted in significant variations in survival endpoints. In the case of the DFS subgroup analysis, a stronger association in the OSCC mixed subsites subgroup, when compared exclusively with the tongue carcinoma subgroup, was observed. Prognostic OSCC studies have classically described tongue carcinomas as those tumours which carry the worst prognosis due to the lymphatic richness and the more pronounced diagnostic delay[@CIT0009]. We relate this finding to the possible existence of residual confounding given that some studies pooled data regarding unspecified oral cancer subsites.

This study dealt with the IHC-based CAIX expression in OSCC tissue as a prognostic but not a predictive biomarker. Nonetheless, recent studies have shed light on its promising value as a predictor of the malignant transformation of some orally potentially malignant disorders, such as oral leukoplakia[@CIT0016]. CAIX as a target is of particular interest in oncology as there are a number of CAIX inhibitors available[@CIT0007]. The interference of the HIF pathway with these inhibitors in OSCC has been poorly explored, nonetheless, according to the recent studies carried out by our group, several CAIX inhibitors which were synthesised on phenolic bis mannich bases and sulphonamides showed promising *in vitro* cytotoxicities in several OSCC cell lines[@CIT0046].

The results from this systematic review and meta-analysis are supported by strong evidence. However, when interpreting the main results from this meta-analysis, some of the limitations of the individual studies cannot be ignored. Some authors recorded ambiguity in the distinction between OS and DSS. In addition, some authors did not directly report HR values in the survival analysis and this had to be approximated. In addition, adjustment for multiple established OSCC risk factors varied widely in the included studies. Despite this, we believe that these results are reliable and more widely applicable. However, further immunohistochemical reports are needed in order to validate this biomarker.

5.. Conclusions {#s0011}
===============

In view of the results obtained, we believe that IHC assessment of CAIX expression may be useful as a prognostic biomarker for OSCC, especially in the case of OS and DFS. These results open up the possibility of using this hypoxia-related protein in the prognosis of OSCC, and in its prevention and early control. Future studies with larger sample sizes and well-designed inclusion criteria are warranted in order to assess the role of CAIX IHC-based expression in determining the prognosis of OSCC.
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